Month: May 2025

NVIDIA and FoxconnNVIDIA and Foxconn Hon Hai Technology Group are working with the Taiwan government to build an AI factory supercomputer that will deliver state-of-the-art NVIDIA Blackwell infrastructure to researchers, startups and industries.Foxconn’s Subsidiary — Big Innovation Company — to Build NVIDIA Blackwell Supercomputer With 10,000 NVIDIA Blackwell GPUs to Deliver a Leap in AI Computing for Taiwan TSMC to Harness Big Innovation Company Cloud AI Infrastructure for Research and Development Taiwan National Science and Technology Council to Invest in Supercomputer to Accelerate AI Development and Adoption Across IndustriesTAIPEI, Taiwan, May 18, 2025 (GLOBE NEWSWIRE) — COMPUTEX — NVIDIA and Foxconn Hon Hai Technology Group today announced they are deepening their longstanding partnership and are working...

 Two New Analyses from SEQUOIA-HCM on Effect of Aficamten Between Patientswith Mild and Moderate-to-Severe Symptoms, and Across Geographic Regions HEOR Analyses of Real-World Data Reveal Disparities in Outcomes In Females and Older Patients with Non-Obstructive HCM SOUTH SAN FRANCISCO, Calif., May 18, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data arising from two analyses from SEQUOIA-HCM, (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), and results from a real-world analysis related to non-obstructive HCM were presented at the European Society of Cardiology Heart Failure 2025 Congress. The results from an...

 Slowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through 24 months Statistically significant correlation between absolute reduction in sorbitol and change in 10MWRT and CMT-FOM Lower Limb domain at 12 months, though the primary endpoint of 10MWRT at 12 months was not statistically significant (the measure has since been removed from the CMT-FOM clinical outcomes assessment based upon the results of the ACT-CMT study*) Statistically significant improvement in CMT-HI and statistically significant correlation between percent change in sorbitol and change in CMT-HI at 12 months Treatment with govorestat in CMT-SORD-Null rats demonstrated a highly statistically significant 37% (p=0.005) reduction of sorbitol in the sciatic nerve, the tissue of interest, after treatment...

Deep, durable and consistent reductions in TTR were sustained at two years, following a one-time dose of nex-z Clinically meaningful improvements in ATTRv-PN related outcomes observed at 24 months compared to baseline, including in patients who were previously progressing on patisiran Continue to observe generally favorable safety and tolerability data in the full Phase 1 cohort with no new drug-related adverse events within the follow-up period Enrollment continues to progress well in MAGNITUDE-2, which is designed to measure clinical outcomes (including mNIS+7) and evaluate how a single dose of nex-z can lead to reduction in serum TTR, to potentially support a BLA submission by 2028CAMBRIDGE, Mass., May 18, 2025 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused...

Data confirmed TX45’s tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”) In new echocardiographic analysis, TX45 treatment resulted in sustained hemodynamic effects for 29 days TX45 improved cardiac and pulmonary hemodynamics in PH-HFpEF patients across a range of left ventricular ejection fractions (“LVEF”), including LVEF≥50% and LVEF 41-49%WATERTOWN, Mass., May 17, 2025 (GLOBE NEWSWIRE) — Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) today announced the complete results from Part A of the Phase 1b clinical trial of TX45 in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”), which are being presented in a late-breaking,...

Data suggests that single dose of RJVA-001 leads to durable metabolic improvements with low systemic GLP-1 exposure in db/db mouse model of T2D— potentially simultaneously addressing durability, adherence, and tolerability challenges seen with current GLP-1 drugs Endoscopic ultrasound-guided delivery achieves targeted pancreatic expression in a large animal model with no toxicity observed to date Data show nutrient-responsive GLP-1 secretion in human beta cells and human islets, demonstrating that Rejuva mimics natural hormone regulation rather than constant drug-driven stimulation Rejuva advancing toward first-in-human studies; first CTA module submission for RJVA-001 expected by June 2025 BURLINGTON, Mass., May 17, 2025 (GLOBE NEWSWIRE) — Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a metabolic therapeutics company focused...

 rcadis 2025 Annual General MeetingArcadis’ shareholders re-appoint Supervisory Board members and approve dividendShareholders re-appointed Michiel Lap and Carla Mahieu to the Supervisory Board Shareholders approved the company’s dividend proposal of €1.00 per ordinary shareAmsterdam, 17 May 2025 – Arcadis (EURONEXT: ARCAD), the world’s leading company in delivering data-driven sustainable design, engineering, and consultancy solutions for natural and built assets, confirms that all resolutions that were brought up for vote were adopted during its annual General Meeting earlier today. Michiel Lap was reappointed to the Supervisory of Arcadis N.V. for a final term of two years. Mr. Lap has been a member of the Supervisory Board since 2015, and Chair of the Supervisory Board since 2022. Mr. Lap will remain Chair of the Supervisory...

VANCOUVER, British Columbia, May 16, 2025 (GLOBE NEWSWIRE) — SHARC International Systems Inc. (CSE: SHRC) (FSE: IWIA) (OTCQB: INTWF) (“SHARC Energy” or the “Company”) is pleased to announce that the Company has entered into a short-term working capital loan agreement for up to $400,000 (the “Loan”). The Loan matures on July 31, 2025, subject to mutual agreement for extension, and bears interest at an annual rate of 8%. The Loan is secured against all present and after acquired assets of the Company. The Loan will be used for working capital purposes as SHARC Energy works through the working capital cycle of several SHARC and PIRANHA projects that are to be delivered over the next three months. In consideration of the Loan, the Company issued 800,000 stock options (the “Options”). Each Option entitles the holder thereof...

VANCOUVER, British Columbia, May 16, 2025 (GLOBE NEWSWIRE) — GoldHaven Resources Corp. (CSE: GOH) (“GoldHaven” or the “Company”) announces that, based upon a review of the Company’s disclosure by the British Columbia Securities Commission (“BCSC”), it wishes to clarify disclosure regarding its Magno and Copecal Projects. The Company’s voluntarily filed technical reports (the “Reports”) in respect of the Magno project nor the Copecal project (each available under the Company’s profile at www.sedarplus.ca) do not comply with the requirements of NI 43-101, and accordingly the Company advises readers not to rely on the Reports until such time as the Company has been able to re-file each. Further, the Company wishes to clarify that there is no mineral resource in respect of the Magno Project at this time. Qualified PersonR.J. (Bob)...